Hypokalemia News and Research

RSS

AI model could improve screening for primary aldosteronism

A study of a new AI model examining 30 years of routine electronic health records (EHR) data could improve screening for primary aldosteronism, a leading cause of high blood pressure that is often unrecognized but increases patients' risk of cardiovascular complications, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Promising new male birth control pill could be taken every three days

YCT-529, a novel non-hormonal male contraceptive, demonstrates safety and tolerability in early trials, offering a potential solution for male birth control.

28 Jul 2025

AI-designed drug shows early promise for lung fibrosis patients in clinical trial

Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung function in patients with idiopathic pulmonary fibrosis in a 12-week phase 2a clinical trial. The highest dose group demonstrated a trend toward increased forced vital capacity, especially among patients not receiving standard antifibrotic therapy, supporting further clinical investigation.

4 Jun 2025

Potassium analysis with ion chromatography according to USP testing methods

Method validation according to the U.S. Pharmacopeia.

From Metrohm Middle East FZC 24 Feb 2025

Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure

MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients.

3 Sep 2024

Pooled analysis shows finerenone reduces all-cause mortality but not cardiovascular death

A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

$Mineralocorticoid receptor antagonists benefit heart failure patients across ejection fractions$

Mineralocorticoid receptor antagonists benefit heart failure patients across ejection fractions

Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

Fenugreek seeds: A superfood for health and wellness, says new review

Research highlights the dietary significance and potential applications of fenugreek seeds, emphasizing their role in disease prevention, chronic condition management, and providing nutritional value, including their ability to reduce blood sugar and cholesterol levels.

27 Feb 2024

Early initiation of dapagliflozin in acute decompensated heart failure does not improve diuretic efficiency

Early initiation of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual care in hospitalized patients with acute decompensated heart failure (ADHF), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

29 Aug 2023

Novel mathematical model simulates how an average person's body regulates potassium

Having levels of potassium that are too high or too low can be fatal. A new mathematical model sheds light on the often mysterious ways the body regulates this important electrolyte.

30 Jan 2023

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.

13 Dec 2022

Complementary, alternative therapies for heart failure have some benefits and potential risks

There are some benefits and potentially serious risks when people with heart failure use complementary and alternative medicines (CAM), to manage symptoms, so involving the health care team is important for safety, according to a new American Heart Association scientific statement published today in the Association's flagship, peer-reviewed journal Circulation.

8 Dec 2022

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Scientists develop nanoantidote to reduce acidosis in critically ill COVID-19 patients

A group of scientists from China has recently developed an antacid nanoantidote that can effectively ameliorate blood acidosis induced by SARS-CoV-2 infection.

11 Aug 2022

Maintaining serum potassium level may lower hazard of peritonitis in patients receiving peritoneal dialysis

This prospective, multicenter, randomized controlled trial published in the American Journal of Kidney Diseases (AJKD) demonstrated that, compared with a reactive strategy of potassium supplementation when serum potassium fell below 3.5 mEq/L, a protocol-based potassium supplementation strategy to maintain serum potassium in the target range of 4-5 mEq/L resulted in a longer time (90 days) to the first peritonitis episode, a lower hazard ratio of peritonitis, and a lesser proportion of free-peritonitis participants.

18 May 2022

First interchangeable biosimilar insulin product approved by FDA for treatment of diabetes

Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus.

28 Jul 2021

Furin inhibition may mitigate severe COVID-19, study finds

Dr. Kara Fitzgerald, a researcher at the Institute for Functional Medicine in the United States, has explained the role of furin protease in developing severe COVID-19 illness.

20 Nov 2020

COVID-19 linked to type 1 diabetes and diabetic ketoacidosis in children

A team of researchers at Imperial College Healthcare NHS Trust and Imperial College London has found a link between COVID-19 and new-onset type 1 diabetes in children. The research is published in the journal Diabetes Care.

20 Aug 2020

Low potassium levels in COVID-19 disease

Now a new study by an Italian team of researchers published in June 2020 on the preprint server medRxiv reports that potassium levels are often low in COVID-19 disease, mostly due to the urinary loss of potassium.

17 Jun 2020

Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?

The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.

20 Apr 2020